LYSOGENE: directors' dealings · France · AMF

About LYSOGENE

Lysogene is a French biotechnology company focused on gene therapy, with a historical specialization in rare central nervous system disorders, particularly pediatric lysosomal storage diseases. Founded in 2009 in Paris by Karen Aiach, the company was created from a highly personal mission: to develop a treatment for a rare disease affecting a family member. Since then, Lysogene has positioned itself as an R&D-driven biotech platform dedicated to designing innovative therapies based on adeno-associated virus (AAV) vectors, aiming to correct the underlying genetic causes of severe orphan diseases. The company’s core business has centered on developing gene therapies for high-unmet-need indications. Its flagship program for many years was LYS-GM101, a gene therapy candidate designed for GM1 gangliosidosis, a rare and severe neurodegenerative disorder. Lysogene has also pursued other CNS-focused rare disease programs, including work in selected forms of Sanfilippo syndrome, reflecting its scientific expertise in complex inherited disorders. The business model was therefore largely dependent on research and development, scientific partnerships, value creation from clinical progress, and investor perception tied to regulatory and clinical milestones rather than recurring product sales. From a competitive standpoint, Lysogene belonged to a highly specialized group of clinical-stage biotechs, where differentiation depends on the quality of preclinical and clinical data, expertise in viral vector engineering, and the ability to finance long, expensive development timelines. The company was one of the more visible European names in gene therapy, although it remained small relative to large pharmaceutical groups and some global biotech peers. Its investment appeal came primarily from the potentially transformative nature of its product candidates rather than from commercial revenues. Geographically, Lysogene was based in France, with headquarters in the Paris area, while its development efforts were international in scope, involving collaborations with specialized centers, industrial contractors, and regulatory stakeholders in Europe and the United States. A notable fact is that Lysogene became one of the emblematic French biotechs in the rare neurological disease segment. However, based on the most recent information available in the sources consulted, the company later entered judicial liquidation proceedings, representing a major turning point in its industrial and financial trajectory, despite the scientific relevance of the work it carried out.